ROCKVILLE, Md.--(BUSINESS WIRE)--The AIM-HI Accelerator Fund, an emerging non-profit impact-investment organization committed to advancing early-stage, oncology companies, is pleased to announce an important update to its Board of Directors (BOD) leadership.
Matt Tremblay, Ph.D., Chief Executive Officer of Blackbird Laboratories, has been appointed as Chair of the Board and Rose Wang, MBA, CEO of 1104 Health and Founder of Binary Group, has been appointed as a new AIM-HI Board Director. These Board appointments bring in multidisciplinary expertise, enabling AIM-HI to leverage new partnerships and collaboration networks to foster continued innovation for cancer drug development.
Dr. Tremblay brings a wealth of experience to the position, having previously served as Chief Operating Officer of Scripps Research and its drug discovery division Calibr, where he led business development, operations, and research strategy. His experience in shaping strategic visions and fostering business growth uniquely positions him to support AIM-HI's mission to accelerate cancer drug discovery and development.
Ms. Wang is a serial entrepreneur and an advocate for women’s leadership in business sectors. She is the Founder & CEO of 1104Health, a digital health company with a mission to democratize access for all cancer patients to disease specialists, cutting-edge clinical studies, and accurate and trustworthy information about their disease and care, regardless of where they live or socioeconomic status. Prior to this role, as the Founder of Binary Group, an IT consulting firm, she was appointed to the National Women’s Business Council (NWBC), a non-partisan federal advisory council established under H.R.5050 for two terms. She has been a strong proponent for empowering women in entrepreneurship, which aligns seamlessly with AIM-HI's values.
“I look forward to working with Dr. Tremblay and Ms. Wang as we embark on the innovative journey of making impact investments and building the eco-system to support the early-stage oncology companies,” said Sujuan Ba, Ph.D., the CEO and Co-Founder of AIM-HI, and President and CEO of the National Foundation for Cancer Research. “Their expertise will play a pivotal role in guiding AIM-HI in cultivating scientific and entrepreneurial partnerships towards bringing life-saving treatments to cancer patients.”
Dr. Tremblay added, "I am honored and excited to take on the role of AIM-HI Board Chair. We are grateful to NFCR for their steadfast support of the AIM-HI Accelerator Fund since its inception. AIM-HI has made tremendous progress in a very short period of time. As a collaboration between AIM-HI and NFCR, this work stands as a testament to our shared commitment to propelling pioneering cancer research from the laboratory to the forefront of patient care. By fostering the translation of breakthrough discoveries into innovative treatments, we collectively work towards redefining the landscape of cancer care and offering renewed hope to individuals and families worldwide.”
Also, the AIM-HI organization extends its heartfelt gratitude and a fond farewell to Yajun Xu, Ph.D., who recently finished her term of service, for her outstanding guidance as a member of the Board of Directors at its inception. Dr. Xu's more than two decades of experience in therapeutic programs and founding successful companies have greatly contributed to AIM-HI's mission. Dr. Xu's expertise and guidance have been invaluable during her tenure as an AIM-HI Board Director, and her impact will undoubtedly continue to resonate within the organization.
Dr. Ba concluded, “These strategic changes to the AIM-HI Board of Directors reinforce the organization’s commitment to building the eco-system and collaborative platform that provides critically needed seed investments and invaluable guidance and network to the entrepreneurs and leaders of the oncology companies.”
For more information about AIM-HI and its Board of Directors, please visit the AIM-HI website.
About the AIM-HI Accelerator Fund
The AIM-HI Accelerator Fund (AIM-HI) is an independent 501(C)(3) non-profit organization created in 2019 by the National Foundation for Cancer Research to provide oncology startups with the resources they need to drive innovative discoveries forward, out of the lab, to the clinics, and eventually to the people battling cancer. Our non-profit changes the paradigm of funding biotech startups, utilizing charitable giving to make impact investments. Our mission is to bridge the gap between research breakthroughs and clinical trials, with the ultimate goal of developing innovative cancer therapies and technologies that can save patients’ lives. For more information, visit https://aim-hiaccelerator.org/.
About the National Foundation for Cancer Research
The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization that provides scientists in the lab the funding they need to make breakthrough discoveries in cancer treatments, detection, prevention and ultimately, a cure for all cancer. NFCR has distinguished itself in the cancer research sector by emphasizing long-term, transformative research often overlooked by other major scientific funding sources. With the help of more than 5.3 million individual donors over the last 50 years, NFCR has provided $410 million in funding to cancer research, prevention, and public education, which has led to many significant and life-saving discoveries that benefit patients today. For more information, visit http://www.nfcr.org.